We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
VistaGen Therapeutics announced positive new data from the Company's second preclinical study of its oral investigational drug, AV-101, in combination with probenecid. Probenecid has extensive data supporting its safe oral delivery and ability to ...